Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 May 21:16:76.
doi: 10.1186/s12883-016-0586-3.

Iranian consensus on use of vitamin D in patients with multiple sclerosis

Soodeh Razeghi Jahromi  1   2 , Mohammad Ali Sahraian  3   4 , Mansoureh Togha  5   6 , Behnaz Sedighi  7 , Vahid Shayegannejad  8 , Alireza Nickseresht  9 , Shahriar Nafissi  10 , Niayesh Mohebbi  11 , Nastran Majdinasab  12 , Mohsen Foroughipour  13 , Masoud Etemadifar  14 , Nahid Beladi Moghadam  15 , Hormoz Ayramlou  16 , Fereshteh Ashtari  8 , Shekoofe Alaie  1
Affiliations
Review

Iranian consensus on use of vitamin D in patients with multiple sclerosis

Soodeh Razeghi Jahromi et al. BMC Neurol. .

Abstract

Background: Accumulating evidences from experimental, epidemiologic and clinical studies support the potential linkage between poor vitamin D status and the risk of developing Multiple Sclerosis (MS), as well as, an adverse disease course. However, the results of the trials on the clinical outcomes of vitamin D supplementation in MS patients are less consistent which brought many discrepancies in routine practice. In this article we presented a summary of a symposium on vitamin D and MS. In this symposium we aim to review the current data about the relationship between vitamin D and MS, and suggest management guides for practicing neurologists.

Discussion: Generally, supplementation seems to be reasonable for all MS and clinically isolated syndrome (Rinaldi et al., Toxins 7:129-37, 2015) patients with serum 25(OH)D level below 40 ng/ml. In patients with vitamin D insufficiency or deficiency, a large replacing dose (e.g. 50,000 IU capsules of D per week for 8-12 week) is recommended. Panel also suggested: the checking of the serum vitamin D, and calcium level, as well as, patients' compliance after the initial phase; a maintenance treatment of 1500-2000 IU daily or equivalent intermittent (weekly, biweekly or monthly) Dose, considering the patient's compliance; routine check of serum vitamin D level at least two times a year especially at the beginning of spring and autumn; Serum vitamin D evaluation for first degree relatives of MS patients at high risk age and supplementation in case of insufficiency (25(OH)D less than 40 ng/ml); correction of vitamin D deficiency and insufficiency before pregnancy, as well as, a daily dose of 1500-2000 IU or equivalent biweekly intake in 2nd and 3rd trimesters; stopping supplementation if 25(OH)D serum level exceeds 100 ng/ml. Although the results of high power studies are not available, correcting vitamin D status seems plausible in all MS and CIS patients. Maintaining the serum 25(OH)D level between 40 and 100 ng/ml is not known to exert adverse effect. More ever, it might be associated with lower disease activity.

Keywords: Assessment; Etiology; Multiple sclerosis; Pathogenesis; Treatment; Vitamin D.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Rinaldi AO, Sanseverino I, Purificato C, Cortese A, Mechelli R, Francisci S, et al. Increased circulating levels of vitamin D binding protein in MS patients. Toxins. 2015;7(1):129–137. doi: 10.3390/toxins7010129. - DOI - PMC - PubMed
    1. Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357(3):266–281. doi: 10.1056/NEJMra070553. - DOI - PubMed
    1. Smolders J, Damoiseaux J, Menheere P, Hupperts R. Vitamin D as an immune modulator in multiple sclerosis, a review. J Neuroimmunol. 2008;194(1):7–17. doi: 10.1016/j.jneuroim.2007.11.014. - DOI - PubMed
    1. Jiao Z, Fu Y, Fu J, Zhang F, Wang W. 1, 25-dihydroxyvitamin D3 promotes the apoptosis of inflammatory cells in acute experimental autoimmune encephalomyelitis: experiment with rats. Zhonghua Yi Xue Za Zhi. 2008;88(33):2350–2354. - PubMed
    1. Pedersen LB, Nashold FE, Spach KM, Hayes CE. 1, 25‐dihydroxyvitamin D3 reverses experimental autoimmune encephalomyelitis by inhibiting chemokine synthesis and monocyte trafficking. J Neurosci Res. 2007;85(11):2480–2490. doi: 10.1002/jnr.21382. - DOI - PubMed